EUCTR2011-005631-20-ES进行中（未招募）1 期
A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 mcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema. - Dexamethasone Posterior Segment Drug Delivery System versus Ranibizumab in Patients with DME
Allergan Ltd0 个研究点目标入组 363 人开始时间: 2012年4月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 363
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female, at least 18 years of age.
- •2.Diagnosis of diabetes mellitus (type 1 or type 2) as defined by the World Health Organization/International Diabetes Federation (Report of a WHO/IDF consultation, 2006)
- •- Fasting plasma glucose level >or = 7.0 mmol/L (126 mg/dL) or
- •- Plasma glucose > or = 11.1 mmol/L (200 mg/dL) 2 hours after a 75 g oral glucose load as in a glucose tolerance test.
- •3.Presence of macular edema associated with diabetic retinopathy defined as macular thickening by optical coherence tomography (OCT) assessed by the investigator in the study eye with the following characteristics:
- •- involving the center of the macula (fovea)
- •- VA decrease attributable to macular edema
- •4.BCVA score > or = 34 and < or = 70 letters (approximately 20/200 to 20/40 on the Snellen scale) using the Early Treatment Diabetic Retinopathy Study (ETDRS) method in the study eye at the screening visit.
- •5.Study eye mean retinal thickness by spectral domain OCT in the 1 mm central macular subfield of > or = 300 mcm with Spectralis (Heidelberg) or 275 mcm with Cirrus (Zeiss) as determined by the investigator at the screening visit.
- •6.(Both Eyes) Media clarity, pupillary dilation, and patient cooperation sufficient for all study procedures.
- •7.Written informed consent has been obtained in accordance with state and country privacy requirements, where applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •Systemic conditions or treatments
- •1. History of disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational drug, might affect the interpretation of study results or render the patient at high risk from treatment complications.
- •2. HbA1c (glycated hemoglobin) >12% at baseline.
- •3. Untreated diabetes mellitus or initiation of oral anti-diabetic medication or insulin within 4 months prior to baseline or anticipated change of anti-diabetic medications during the 1-year study participation.
- •4. Renal failure requiring hemodialysis or peritoneal dialysis within 6 months prior to baseline or anticipated need for hemodialysis or peritoneal dialysis at any time during the study or adjusted glomerular filtration rate < 50 mL/min.
- •5. Use of systemic (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) corticosteroids within 1 month prior to screening.
- •6. Uncontrolled systemic disease
- •Ocular concomitant conditions/disease
- •7. Any current or history of ocular disease in the study eye, other than DME that in the opinion of the investigator may confound assessment of the macula or affect central vision (for example: exudative age-related macular degeneration [AMD], geographic atrophy, macular edema due to retinal vein occlusion, uveitis, angioid streaks, histoplasmosis, active or inactive cytomegalovirus, pathological myopia, retinal detachment, macular traction, macular fibrosis or scarring, macular hole, significant cataract).
- •8. Increased intraocular pressure (IOP >or=22 mmHg) at screening or day 1, or diagnosis of glaucoma.
- •9. Any active ocular inflammation or ocular infection (ie, bacterial, viral, parasitic, or fungal) in either eye at the screening visit.
- •10. Aphakia in the study eye or break in the posterior capsule in the study eye, unless it is a small break resulted from a YAG laser posterior capsulotomy in association with prior posterior intraocular lens implantation
- •11. Anticipated need for ocular surgery in the study eye during the 1-year study participation.
- •12. Active proliferative diabetic retinopathy and/or rubeosis.
- •13. BCVA score < 34 letters in fellow eye.
- •Ocular treatment
- •14. Laser photocoagulation to the study eye within 3 months prior to screening.
- •15. Use of anti-VEGF treatment in study eye within 3 months prior to screening or use of systemic anti-VEGF within 6 months prior to screening
- •16. Use of intravitreal triamcinolone within 6 months prior to screening.
- •17. Use of topical intraocular, intravitreal (except triamcinolone, see above) or periocular corticosteroids within 3 months prior to screening in the study eye or ocular conditions in the study eye that require chronic concomitant therapy with topical, local ocular or systemically administered corticosteroids.
- •18. History of use of DEX PS DDS within 9 months prior to screening.
- •19. History of cataract surgery within the 3 months prior to baseline.
- •20. History of vitrectomy.
- •21. History of incisional glaucoma surgery.
- •22. Known allergy, hypersensitivity or contraindication to the study medications, its components, fluorescein or povidone iodine.
- •Compliance / administrative.
- •23. Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception.
- •24. Current enrollment in an investigational drug or device study or participation in such
研究者
相似试验
进行中（未招募）
不适用
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.EUCTR2011-005631-20-NLAllergan Ltd300
进行中（未招募）
1 期
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.EUCTR2011-005631-20-BEAllergan Ltd300
进行中（未招募）
不适用
Comparison of efficacy and safety of OZURDEX versus Lucentis in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2011-005631-20-ITALLERGAN LIMITED300
进行中（未招募）
不适用
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.Diabetic Macular EdemaMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersEUCTR2011-005631-20-ATAllergan Ltd300
进行中（未招募）
不适用
Comparison of efficacy and safety of OZURDEX® versus Lucentis® in the treatment of Diabetic Macular Edema.EUCTR2011-005631-20-SEAllergan Ltd300